

Fundamental dimension Equity attribute | BIOELeader $0.420.00% Cap $16.63MP/E 11.3x QuantScore77/100 | CRYMPeer $0.00020.00% Cap $47.43KP/E -0.0x QuantScore35/100 | LMLLFPeer $0.00340.00% Cap $456.3KP/E -0.9x QuantScore35/100 |
|---|---|---|---|
1. QuantScore pillars0–100 per pillar · click a ticker for the factor breakdown | |||
Technical | |||
73/100 |
84/100 |
38/100 |
Valuation Multiples, PEG & DCF upside | 77/100 | 0/100 | 33/100 |
Health Piotroski, Altman Z, leverage & liquidity | 60/100 | 23/100 | 20/100 |
Growth Revenue / earnings growth & margins | 100/100 | 33/100 | 50/100 |
Sentiment Analyst ratings, targets & revisions | — | — | — |
2. Valuation multiples & capital pricingGreen highlight = best-in-class (lowest positive multiple) |
Trailing P/E | 11.3x | -0.0x | -0.9x |
Forward P/E (next FY) | — | — | — |
EV / EBITDA (TTM) | 11.1x | -0.4x | -10.2x |
Price / Sales | 5.7x | 3.5x | — |
Price / Free Cash Flow | 15.5x | -0.0x | -7.5x |
PEG ratio | 0.01 | -0.00 | 0.01 |
3. Financial health & solvencyLatest filings |
Piotroski F-Score | 6 / 9 | 3 / 9 | 2 / 9 |
Altman Z-Score | 4.46 (Safe) | -102.23 (Distress) | -78.47 (Distress) |
Total debt / equity | 0.67 | -0.77 | -0.95 |
Quick ratio | 0.4x | 0.1x | 0.0x |
Interest coverage | 706.6x | -27.7x | -0.6x |
4. Growth & margins trajectoryLatest fiscal year |
Revenue growth YoY | +485.8% | — | — |
Net income growth YoY | +168.5% | -24.3% | +51.7% |
Gross margin (TTM) | 69.7% | 100.0% | 0.0% |
Operating margin (FY) | 47.4% | -79560.2% | — |
FCF margin (FY) | 82.7% | -28624.7% | — |
5. Trailing price performancePrice change over period |
1M return | +130.8% | +0.0% | -22.7% |
3M return | +55.6% | +0.0% | -34.0% |
6M return | -6.7% | +0.0% | -68.5% |
Year to date | +600.0% | +0.0% | -61.8% |
1Y return | +508.7% | +19900.0% | -64.9% |
3Y return | -17.6% | -99.8% | -81.3% |
6. DCF valuation & street consensusDCF model · analyst consensus |
DCF model fair value | $-0.1693 -140.3% premium | $-0.0311 -15632.3% premium | $-0.0121 -454.5% premium |
Wall Street consensus target | — — | — — | — — |
Consensus stance | — | — | — |